中生製藥(01177.HK):創新藥“TCR1672”已向FDA提交IND申請並獲受理
格隆匯10月8日丨中國生物製藥(01177.HK)宣佈,集團自主研發的創新藥“TCR1672”已向美國食品藥品監督管理局("FDA")提交試驗用新藥("IND")申請並獲得受理。TCR1672為二代高選擇性的P2X3受體拮抗劑,目前主要應用於治療呼吸領域的難治性慢性咳嗽(RCC)成年患者及疼痛領域的子宮內膜異位症等複雜性內臟痛患者。
P2X3受體是嘌呤類受體家族中的配體門控離子通道。研究顯示,P2X3受體的過度活化與感覺神經元的超敏化(hyper-sensitization)有關。損傷或感染引發的氣道和肺部神經元超敏反應可引起過度、持續和頻繁地咳嗽。TCR1672通過阻斷三磷酸腺苷(ATP)啟動P2X3受體產生的鈣離子內流,從而發揮對其特異性抑制作用來起到治療效果。
截至目前,全球尚未有P2X3抑制劑獲批,相關產品存在巨大的市場潛力。TCR1672臨牀試驗的啟動,將進一步豐富集團在呼吸領域和疼痛領域的創新產品管線,為廣大患者帶來新的治療希望。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.